James Boyle is William Neal Reynolds Professor of Law at the Duke Law School. He has also taught at American University, Yale, Harvard, and at the University of Pennsylvania Law School. His recent work has been on the legal issues posed by the commodification of all forms of information: from genetic and cultural, to electronic and commercial. His book on the subject, Shamans, Software and Spleens: Law and the Construction of the Information Society, was published by Harvard University Press. His most recent article Fencing off Ideas? The Second Enclosure Movement appeared in Daedalus, the American Academy of Arts and Sciences journal, earlier this year. He is a member of the advisory board of the Electronic Privacy & Information Center, and the Board of Creative Commons. He is currently working on a book called The Public Domain. http://james-boyle.com

Allen Buchanan

Barbara Caulfield

Robert Cook-Deegan, MD, is director of the Center for Genome Ethics, Law, and Policy at Duke University. Until July 2002, he directed the Robert Wood Johnson Foundation Health Policy Fellowship program at the Institute of Medicine (IOM), National Academy of Sciences. He is also a Robert Wood Johnson Health Policy Investigator at the Kennedy Institute of Ethics, Georgetown University, where he is completing a primer on how national policy decisions are made about health research. He has taught a seminar for the Stanford-in-Washington program since early 1997, and with two Stanford students recently directed a world survey of genomics research.
- Symposium presentation - DNA Patents: Benefits, Obstacles and Policy Options (PowerPoint) (Adobe Acrobat)

Daniel Drell

Lila Feisee is director of federal government relations and intellectual property at BIO, the largest trade organization representing the biotechnology industry. BIO members include companies, academic institutions, state biotechnology centers and affiliated organizations in 50 states and 33 nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products. Before joining BIO, Ms. Feisee worked for 10 years at the United States Patent and Trademark Office (PTO), first as an examiner and later in management and policy development. Her primary areas of expertise are protein engineering, therapeutics and assays. Ms. Feisee was instrumental in developing both the guidelines for Utility and Written Description and related training materials. Ms. Feisee also worked at the National Institutes of Health in the National Cancer Institute, Laboratory of Genetics where she isolated and characterized viral and human oncogenes. Ms. Feisee received her B.S. degree in Biology from the University of Virginia and an M.S. degree in Genetics from the George Washington University School of Medicine

Peter Newmark, PhD has a BA and PhD in Biochemistry from Oxford University. He joined Nature as Biology Editor in 1974 and left as Deputy Editor in 1990 to join the Current Science Group. There he managed the Current Opinion review journals and founded and edited the journal Current Biology. In 1997, he moved with these journals to Elsevier Science and became responsible also for the Trends review journals. In 2000, he returned to the Current Science Group as Biology Editorial Director for BioMed Central, the pioneering open-access publisher.

Arti Rai

Jerome Reichman

Alex Rosenberg, PhD joined the Duke faculty in 2000. Previously, he was professor of philosophy at Syracuse University, University of California, Riverside and Director of the Honors Program at the University of Georgia. Professor Rosenberg has also been a visiting professor and fellow of the Center for Philosophy of Science at the University of Minnesota, as well as the University of California, Santa Cruz, and Oxford University. His interests focus on problems in metaphysics, mainly surrounding causality, the philosophy of social sciences, especially economics, and most of all, the philosophy of biology, in particular the relationship between molecular, functional and evolutionary biology. He serves as co-director of the Duke University Center for the Philosophy of Biology.

Patrick Terry is the co-founder and Director of Consumer Advocacy & Governmental Affairs at Genomic Health, Inc. (www.genomichealth.com), and brings the wisdom of a perspective forged from personal experience and extensive work in the lay advocacy community. In 1995, he and his wife, Sharon, discovered their two children had a rare condition, pseudoxanthoma elasticum (PXE). Following that diagnosis, they founded PXE International (www.pxe.org), a dynamic international lay organization that initiates, funds, and coordinates worldwide biomedical research. He is also co-founder and President of the International Genetic Alliance (www.internationalgeneticalliance.org) that focuses on empowering problem solving by networking the consumer movement, centers of excellence, and high technology with disenfranchised communities, indigenous peoples and third world countries.

Sharon Terry, MA is President of the Genetic Alliance and the founding executive director of PXE International, a lay advocacy group for the genetic condition, pseudoxanthoma elasticum (PXE). Following the diagnosis of their two children with PXE in 1995, Sharon and her husband, Patrick, founded and built a dynamic organization that fosters ethical research and policy as well as support for members and the public. In five years, PXE International established and directs a 19-research lab consortium, 52 offices worldwide, a blood and tissue bank, a database of thousands of affected individuals, and many important services for affected individuals. Sharon co-authored a number of papers including two papers on the discovery of the PXE gene, published in Nature Genetics, June 2000. She is a co-inventor of the 'PXE gene' (ABCC6) and has filed a patent application for the invention. Sharon Terry also serves as an Ethical, Legal, and Social Implications Research Advisor of NHGRI/NIH, is a member of other governmental advisory committees on genetics, is a member of the board of directors of the Biotechnology Institute, and is president of the Coalition of Heritable Disorders of Connective Tissue.

Max N. Wallace is the President and CEO of Cogent Neuroscience, Inc. Mr. Wallace has been involved in the creation and development of successful biotechnology companies for more than fifteen years. Prior to co-founding Cogent Neuroscience in 1998, Mr. Wallace co-founded SARCO (small molecule combinatorial chemistry) in 1996, Trimeris (viral fusion inhibition) in 1993 and Sphinx Pharmaceuticals (cellular signal transduction) in 1986. At both Trimeris and SARCO, Mr. Wallace served as President and as a member of the Board of Directors. Sphinx Pharmaceuticals had a successful public offering and was subsequently acquired by Eli Lilly & Co. Trimeris had successful initial and secondary public offerings and, with partner Hoffman LaRoche, is moving its first two anti-HIV drugs through clinical trials. SARCO was acquired by PPD/Pharmaco. A founding management director of Duke Management Company, Duke University's asset management company, Mr. Wallace received his B.A. from Duke University and his J.D. from the University of Florida.